Immunohistochemical Evaluation of Breast Cancer Biomarkers

We performed an immunohistochemistry (IHC) using tissues obtained before treatment. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), p53, bcl-2, and Ki-67 expressions were evaluated. IHC was performed as previously described [14 (link),22 (link)]. ER and PR positivity was defined as ≥10% positive tumor cells with nuclear staining. HER2 positivity was defined as either HER2 gene amplification by fluorescent in situ hybridization or scored as 3+ by IHC [23 (link)]. In case of HER2 2(+), fluorescent in situ hybridization was performed to determine HER2 positivity. TNBC was defined as ER(-), PR(-), and HER2(-), regardless of the expression of EGFR and basal cytokeratins. Only cytoplasmic staining was scored as positive for bcl-2, regardless of the intensity of the stained cells. Cells stained for Ki-67 and p53 were counted and expressed as a percentage. The percentage was determined by the number of Ki-67 positive cells among the total number of counted tumor cells. High expression of Ki-67 was defined as ≥10%, because 10% as cutoff provided the best prognosis-prediction results in our institute [14 (link)]. Specimens with no residual invasive carcinoma in the both breast and lymph nodes were classified as pathologic complete response (pCR). Residual ductal carcinoma in situ was also included in the pCR category [24 (link)]. Otherwise the specimens which did not achieve pCR category were classified as residual disease

Free full text: Click here

Keam B., Im S.A., Lee K.H., Han S.W., Oh D.Y., Kim J.H., Lee S.H., Han W., Kim D.W., Kim T.Y., Park I.A., Noh D.Y., Heo D.S, & Bang Y.J. (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Research : BCR, 13(2), R22.

Publication 2011

Corresponding Organization :

Other organizations : Seoul National University

Top 5 similar protocols

Protocol cited in 12 other protocols

Variable analysis

independent variables

Treatment (before vs. after)

dependent variables

Estrogen receptor (ER) expression
Progesterone receptor (PR) expression
Human epidermal growth factor receptor 2 (HER2) expression
P53 expression
Bcl-2 expression
Ki-67 expression
Pathologic complete response (pCR)

control variables

IHC protocol as previously described [14, 22]
ER and PR positivity defined as ≥10% positive tumor cells with nuclear staining
HER2 positivity defined as either HER2 gene amplification by fluorescent in situ hybridization or scored as 3+ by IHC [23]
TNBC defined as ER(-), PR(-), and HER2(-), regardless of the expression of EGFR and basal cytokeratins
Cytoplasmic staining scored as positive for bcl-2, regardless of the intensity
High expression of Ki-67 defined as ≥10%
Specimens with no residual invasive carcinoma in both breast and lymph nodes classified as pCR, including residual ductal carcinoma in situ [24]

controls

Positive control: IHC protocol as previously described [14, 22]
Negative control: Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!